[go: up one dir, main page]

ITMI920973A1 - Derivati di adenosina ad attivita' a2 agonista - Google Patents

Derivati di adenosina ad attivita' a2 agonista

Info

Publication number
ITMI920973A1
ITMI920973A1 IT000973A ITMI920973A ITMI920973A1 IT MI920973 A1 ITMI920973 A1 IT MI920973A1 IT 000973 A IT000973 A IT 000973A IT MI920973 A ITMI920973 A IT MI920973A IT MI920973 A1 ITMI920973 A1 IT MI920973A1
Authority
IT
Italy
Prior art keywords
hydrogen
alkyl
pct
cycloalkyl
phenyl
Prior art date
Application number
IT000973A
Other languages
English (en)
Inventor
Gloria Cristalli
Original Assignee
Schering Plough S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough S P A filed Critical Schering Plough S P A
Publication of ITMI920973A0 publication Critical patent/ITMI920973A0/it
Priority to ITMI920973A priority Critical patent/IT1254915B/it
Priority to JP5518886A priority patent/JPH07508718A/ja
Priority to ES93911492T priority patent/ES2145774T3/es
Priority to EP93911492A priority patent/EP0637315B1/en
Priority to US08/325,201 priority patent/US5593975A/en
Priority to DE69328722T priority patent/DE69328722T2/de
Priority to CA002134067A priority patent/CA2134067A1/en
Priority to PCT/EP1993/000972 priority patent/WO1993022328A1/en
Priority to AT93911492T priority patent/ATE193299T1/de
Publication of ITMI920973A1 publication Critical patent/ITMI920973A1/it
Application granted granted Critical
Publication of IT1254915B publication Critical patent/IT1254915B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
ITMI920973A 1992-04-24 1992-04-24 Derivati di adenosina ad attivita' a2 agonista IT1254915B (it)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ITMI920973A IT1254915B (it) 1992-04-24 1992-04-24 Derivati di adenosina ad attivita' a2 agonista
US08/325,201 US5593975A (en) 1992-04-24 1993-04-21 Adenosine derivatives having A2 agonist activity
ES93911492T ES2145774T3 (es) 1992-04-24 1993-04-21 Derivados de adenosina que tienen actividad agonista en a2.
EP93911492A EP0637315B1 (en) 1992-04-24 1993-04-21 Adenosine derivatives having a2 agonist activity
JP5518886A JPH07508718A (ja) 1992-04-24 1993-04-21 Ａ↓２アゴニスト活性を有するアデノシン誘導体
DE69328722T DE69328722T2 (de) 1992-04-24 1993-04-21 Adenosinderivate mit a2 agonistwirkung
CA002134067A CA2134067A1 (en) 1992-04-24 1993-04-21 Adenosine derivatives having a2 agonist activity
PCT/EP1993/000972 WO1993022328A1 (en) 1992-04-24 1993-04-21 Adenosine derivatives having a2 agonist activity
AT93911492T ATE193299T1 (de) 1992-04-24 1993-04-21 Adenosinderivate mit a2 agonistwirkung

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI920973A IT1254915B (it) 1992-04-24 1992-04-24 Derivati di adenosina ad attivita' a2 agonista

Publications (3)

Publication Number Publication Date
ITMI920973A0 ITMI920973A0 (it) 1992-04-24
ITMI920973A1 true ITMI920973A1 (it) 1993-10-24
IT1254915B IT1254915B (it) 1995-10-11

Family

ID=11363039

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI920973A IT1254915B (it) 1992-04-24 1992-04-24 Derivati di adenosina ad attivita' a2 agonista

Country Status (9)

Country Link
US (1) US5593975A (it)
EP (1) EP0637315B1 (it)
JP (1) JPH07508718A (it)
AT (1) ATE193299T1 (it)
CA (1) CA2134067A1 (it)
DE (1) DE69328722T2 (it)
ES (1) ES2145774T3 (it)
IT (1) IT1254915B (it)
WO (1) WO1993022328A1 (it)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
GB9813540D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
JP2002173427A (ja) * 1998-09-01 2002-06-21 Yamasa Shoyu Co Ltd 眼疾患治療用医薬組成物
MXPA01007850A (es) * 1999-02-01 2002-08-20 Univ Virginia Composiciones para tratar respuesta inflamatoria.
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
RU2258071C2 (ru) * 1999-05-24 2005-08-10 Юниверсити Оф Вирджиния Пэйтент Фаундейшн Производные 2-алкиниладенозина для борьбы с воспалительной реакцией
US6322771B1 (en) * 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6180615B1 (en) 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
US20020012946A1 (en) 2000-02-23 2002-01-31 Luiz Belardinelli Method of identifying partial agonists of the A2A receptor
AU2001278708A1 (en) * 2000-09-08 2002-03-22 Toa Eiyo Ltd. Adenosine derivatives and use thereof
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
BR0206464A (pt) * 2001-01-16 2005-01-18 Vascular Therapies Llc Aparelho e processos para impedir ou tratar insuficiência de acesso vascular para hemodiálise e outros enxertos vasculares
NZ556354A (en) * 2001-10-01 2008-10-31 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
GB0129273D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
MXPA05001123A (es) * 2002-07-29 2005-04-29 Cv Therapeutics Inc Formacion de imagenes por perfusion de miocardio mediante el uso de agonistas receptores de a2a.
US20050033044A1 (en) * 2003-05-19 2005-02-10 Bristol-Myers Squibb Pharma Company Methods for preparing 2-alkynyladenosine derivatives
EP1678181B1 (en) * 2003-10-31 2008-12-31 Cv Therapeutics, Inc. A2b adenosine receptor antagonists
TWI346109B (en) * 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
NZ585697A (en) 2004-08-02 2011-12-22 Univ Virginia Patent Found 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
CN101076343A (zh) * 2004-10-20 2007-11-21 Cv医药有限公司 A2a腺苷受体激动剂的应用
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
CN102260311A (zh) 2006-02-03 2011-11-30 吉利德帕洛阿尔托股份有限公司 制备一种a2a型腺苷受体激动剂及其多晶形物的方法
WO2007092936A2 (en) * 2006-02-08 2007-08-16 University Of Virginia Patent Foundation Method to treat gastric lesions
US8178509B2 (en) 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
CA2649215A1 (en) 2006-04-21 2007-11-01 Novartis Ag 2,6,9-trisubstituted purine compounds as adenosine aza receptor modulators
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
WO2008063712A1 (en) * 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
JP2010502649A (ja) * 2006-09-01 2010-01-28 シーブイ・セラピューティクス・インコーポレイテッド 心筋層画像化法中の患者の耐性を増加させるための方法および組成物
EP1903044A1 (en) 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
JP2011502101A (ja) * 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド 肺疾患の病歴を有する患者における心筋画像化法
MX2009007071A (es) * 2007-01-03 2009-10-13 Cv Therapeutics Inc Elaboracion de imagen de perfusion del miocardio.
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
US20110064671A1 (en) 2008-03-10 2011-03-17 Cornell University Modulation of blood brain barrier permeability
MX2011003168A (es) * 2008-09-29 2011-05-19 Gilead Sciences Inc Combinaciones de un agente de control de cantidad y un antagonista del receptor a-2-alfa para utilizarse en metodos de tomografia computarizada de detectores multiples.
EA201270102A1 (ru) 2009-06-30 2012-08-30 Форест Лэборетериз Холдингз Лимитед Соединения алкокси-карбонил-амино-алкинил-аденозина и их производные в качестве агонистов ar
US9822141B2 (en) 2012-08-01 2017-11-21 Lewis And Clark Pharmaceuticals, Inc. N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists
WO2014022577A1 (en) 2012-08-01 2014-02-06 Lewis And Clark Pharmaceuticals, Inc. N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as a2a agonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6299395A (ja) * 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd ２−アルキニルアデノシンおよび抗高血圧剤
EP0267878A1 (en) * 1986-11-14 1988-05-18 Ciba-Geigy Ag N9-cyclopentyl-substituted adenine derivatives
EP0277917A3 (en) * 1987-02-04 1990-03-28 Ciba-Geigy Ag Certain adenosine 5'-carboxamide derivatives
LU87181A1 (fr) * 1987-04-06 1988-11-17 Sandoz Sa Nouveaux derives de l'acide furannuronique,leur preparation et leur utilisation comme medicaments
US5034381A (en) * 1988-01-07 1991-07-23 Ciba-Geigy Corporation 2-(substituted amino) adenosines as antihypertensives
ZA902280B (en) * 1989-03-29 1990-12-28 Merrell Dow Pharma Selective adenosine receptor agents

Also Published As

Publication number Publication date
ES2145774T3 (es) 2000-07-16
EP0637315B1 (en) 2000-05-24
IT1254915B (it) 1995-10-11
EP0637315A1 (en) 1995-02-08
WO1993022328A1 (en) 1993-11-11
DE69328722T2 (de) 2000-12-14
ATE193299T1 (de) 2000-06-15
CA2134067A1 (en) 1993-11-11
DE69328722D1 (de) 2000-06-29
JPH07508718A (ja) 1995-09-28
ITMI920973A0 (it) 1992-04-24
US5593975A (en) 1997-01-14

Similar Documents

Publication Publication Date Title
ITMI920973A1 (it) Derivati di adenosina ad attivita' a2 agonista
ATE194839T1 (de) Pyridinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
NO933452L (no) Et terapeutisk middel for Parkinson's sykdom
DK0641328T3 (da) Broforbundne, azabicykliske derivater som substans P-antagonister
ATE204269T1 (de) Substituierte biphenyl- oder phenylpyridinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
HUP0001062A2 (hu) NAALADáz gátló hatású foszfinsavszármazékokat tartalmazó gyógyászati készítmények
PT674621E (pt) Enantiomeros de derivados de carbazolo como agonistas do tipo 5-ht
DE69632193D1 (de) Cyclooxygenaseinhibitor und salze von amidinderivaten, verfahren zu deren herstellung, deren verwendung als arzneiwirkstoffe sowie diese salze enthaltende arzneimittel
GR3034769T3 (en) Triazole antifungal agents.
ATE168105T1 (de) Melamine derivate zur verwendung in der behandlung von krebs
MX9203939A (es) Derivados de hidroisoquinolina y composiciones farmaceuticas que los contienen.
KR950700287A (ko) 스테로이드 5알파-리덕타아제 억제제로서의 인돌 유도체(Indole Derivatives as Steroid 5 Alpha-Reductase Inhibitors)
KR910011259A (ko) 뉴모시스토시스 치료 또는 예방에 사용하기 위한 플루오로퀴놀론 유도체로 구성된 약제
DE59209175D1 (de) Verwendung von prostacyclin-derivaten zur verhinderung oder behandlung von störungen der mikrozirkulation bei gabe von röntgen-, nmr- oder ultraschallkontrastmitteln
DE69719974D1 (de) Chinolinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE59304311D1 (de) N-substituierte 3-azabicyclo[3.2.0]heptan-derivate als neuroleptika
HUP0001773A2 (hu) Szubsztituált tetrahidropiridinszármazékok, eljárás előállításukra, továbbá a vegyületeket tartalmazó gyógyászati készítmények
PT100682A (pt) Agentes anti-helminticos derivados de benzimidazole e processo para a sua preparacao
DK0623118T3 (da) Carbamatderivater og deres anvendelse i medicin
ATE99326T1 (de) N-phenyl-n-alkoxycarbonylalkyl-glycinamide, ihre herstellung und sie enthaltende medikamente.
MX9303607A (es) Derivados de azabicicloheptano sustituidos, su obtencion y uso.
HUT42099A (en) Process for preparing 2,3-diamino-2,3-dideoxy-hexose derivatives and pharmaceutical compositions containing thereof as active substances
HUT77767A (hu) Imidazolszármazékok új alkalmazása, imidazolszármazékok, eljárás előállításukra és a kapott új köztitermékek, gyógyszerkénti alkalmazásuk, és az ezeket tartalmazó gyógyászati készítmények
ES2102190T3 (es) Metilbutoxi-propionitrilos y su uso como perfumes.
DE3764330D1 (de) 2,2;6,6-diethylen-3-oxo-17alpha-pregn-4-en-21, 17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharm. praeparate.

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970329